Scientists recently developed circular, dual-targeting multivalent aptamer-drug hybrids (o-mvApDHs) to overcome the limitations of traditional targeted drug conjugates (TDCs). These innovative scaffolds simultaneously target the c-Met and CD71 receptors on tumor cells. Consequently, they achieve superior tumor-specific uptake compared to conventional single-antigen designs. This breakthrough provides a versatile platform for precision therapeutics in heterogeneous tumors.

The system effectively codelivers doxorubicin (Dox) and a potent STING agonist known as diABZI. While doxorubicin induces genotoxic stress and immunogenic cell death (ICD), diABZI activates the cGAS-STING signaling pathway. Therefore, this dual approach triggers a robust type I interferon response within the tumor. This coordinated action is vital for disrupting tumor defense mechanisms.

Enhancing Synergy with Multivalent Aptamer-Drug Hybrids

This programmable DNA platform remodels the immunosuppressive tumor microenvironment significantly. It specifically expands populations of IFN-responsive macrophages and recruits conventional dendritic cells. Furthermore, researchers observed increased T-cell receptor (TCR) diversity and a marked reduction in terminal exhaustion among cytotoxic CD8 T cells. Notably, these hybrids synergize with PD-1 blockade to offer durable tumor eradication and long-term protection.

The high loading capacity of these hybrids allows for a precise balance of therapeutic payloads. Because the scaffold uses a programmable DNA structure, clinicians can potentially adapt it for various antigens. This flexibility highlights its potential for next-generation TDC design. Future clinical applications may provide better outcomes for patients with complex, resistant malignancies.

Frequently Asked Questions

How do these hybrids improve upon traditional TDCs?

Traditional TDCs often rely on single-antigen targeting and single-payload architectures. In contrast, these hybrids use dual-targeting (c-Met and CD71) to enhance uptake in heterogeneous tumors and deliver two distinct drugs for a synergistic effect.

What role does the STING agonist play in this therapy?

The STING agonist, diABZI, activates the cGAS-STING pathway to amplify type I interferon responses. This helps convert an immunosuppressive tumor environment into an active one, promoting the recruitment and activation of immune cells like dendritic cells and T cells.

Can these hybrids be combined with other immunotherapies?

Yes, preclinical data show that these hybrids synergize effectively with PD-1 blockade. This combination therapy leads to strengthened effector differentiation and provides long-term protection against tumor recurrence.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Chi H et al. Dual-Targeting Multivalent Aptamer-Drug Hybrids for Synergistic Cancer Immunotherapy. J Am Chem Soc. 2026 Apr 13. doi: 10.1021/jacs.5c21968. PMID: 41973478.

Musson S, Schwartz M. A Proven Strategy of Targeted Therapy: Antibody Drug Conjugates in Cancer Treatment. App Oncology Summit. 2022.

Kaczmarek A et al. STING-Activating Nanoparticles Combined with PD-1/PD-L1 Blockade: A Synergistic Approach in Cancer Immunotherapy. MDPI. 2025.